Lunai Bioworks (纳斯达克: LNAI) 近日宣布,与一家临床阶段的合作伙伴共同启动了一项人工智能肿瘤学试点项目。该项目的核心任务是利用先进的人工智能技术,对一项针对转移性结直肠癌患者的随机II期生存期临床试验数据进行深度分析。此举旨在探索AI在加速肿瘤学研究与药物开发方面的巨大潜力。
Lunai Bioworks (纳斯达克: LNAI) 近日宣布,与一家临床阶段的合作伙伴共同启动了一项人工智能肿瘤学试点项目。该项目的核心任务是利用先进的人工智能技术,对一项针对转移性结直肠癌患者的随机II期生存期临床试验数据进行深度分析。此举旨在探索AI在加速肿瘤学研究与药物开发方面的巨大潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.